This study is being done to find out if adding the chemotherapy drug carboplatin to the standard of care chemotherapy drug cabazitaxel can lower the chance of prostate cancer growing and spreading.
Learn more about the S2312 trial or call the Cancer Research Office at Reading Hospital 484-628-8193.
